Importance of early treatment initiation in the clinical course of multiple sclerosis
- 17 October 2016
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 23 (9), 1233-1240
- https://doi.org/10.1177/1352458516675039
Abstract
Objectives: The aim of this study was to identify factors influencing the long-term clinical progression of multiple sclerosis (MS). A special objective was to investigate whether early treatment decisions influence outcome. Methods: We included 639 patients diagnosed with MS from 2001 to 2007. The median follow-up time was 99 months (8.25 years). Cox regression models were applied to identify factors correlating with the outcome variable defined as time from treatment start to irreversible score 4 of the Expanded Disability Status Scale (EDSS). Results: Patients initiated on treatment later had a greater risk of reaching EDSS 4 (hazard ratio of 1.074 (95% confidence interval (CI), 1.048−1.101)), increased by 7.4% for every year of delay in treatment start after MS onset. Patients who started treatment after 3 years from MS onset reached the outcome sooner with hazard ratio of 2.64 (95% CI, 1.71−4.08) compared with the patients who started treatment within 1 year from MS onset. Baseline EDSS and age at onset were found to be predictive factors of disability progression. Conclusion: Early treatment initiation was associated with a better clinical outcome. In addition, we confirmed the well-established prognostic factors of late age at onset and early disability.Keywords
Funding Information
- Biogen
This publication has 34 references indexed in Scilit:
- Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugsMultiple Sclerosis Journal, 2012
- Evolving expectations around early management of multiple sclerosisTherapeutic Advances in Neurological Disorders, 2010
- A window of opportunity for no treatment in early multiple sclerosis?Multiple Sclerosis Journal, 2010
- Evidence for a two-stage disability progression in multiple sclerosisBrain, 2010
- Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialThe Lancet Neurology, 2009
- Early treatment of multiple sclerosis to prevent neurologic damageNeurology, 2008
- Natural history of secondary-progressive multiple sclerosisMultiple Sclerosis Journal, 2008
- Defining the natural history of MS: the need for complete data and rigorous definitionsMultiple Sclerosis Journal, 2008
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983